Revakinagene Taroretcel (Encelto) – A Gene Therapy for Idiopathic Macular Telangiectasia

Revakinagene taroretcel-lwey (Encelto – Neurotech), an intravitreal allogeneic cell-based gene therapy, has been approved by the FDA for treatment of idiopathic macular telangiectasia type 2 in adults. It is the first treatment to be approved in the US for this indication.

Publication Details

Journal: The medical letter on drugs and therapeutics/The medical letter
Published: 2025-04-28
DOI: https://doi.org/10.58347/tml.2025.1727f
Primary Topic: Retinal and Macular Surgery
Type: article
Field-Weighted Citation Impact: 0.00

Controls

|||

ALL TIME

JAN

FEB

MAR

APR

MAY

JUN

JUL

AUG

SEP

OCT

article

Revakinagene Taroretcel (Encelto) – A Gene Therapy for Idiopathic Macular Telangiectasia

Apr 28, 2025

1 links

The medical letter on drugs and therapeutics/The medical letter

Retinal and Macular Surgery

article

Revakinagene Taroretcel (Encelto) – A Gene Therapy for Idiopathic Macular Telangiectasia

April 28, 2025article en

Abstract

The medical letter on drugs and therapeutics/The medical letterVol. 67(1727)

Openalex Percentile: Top 87%

Retinal and Macular Surgery

DOI Source OpenAlex

AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Revakinagene Taroretcel (Encelto) – A Gene Therapy for Idiopathic Macular Telangiectasia · The medical letter on drugs and therapeutics/The medical letter (2025) | TGRS Research Map | TGRS